Fetal Mesenchymal Stromal Cells: an Opportunity for Prenatal Cellular Therapy

doi:10.1007/s40778-018-0118-8

Review

. 2018;4(1):61-68.

doi: 10.1007/s40778-018-0118-8. Epub 2018 Feb 15.

Fetal Mesenchymal Stromal Cells: an Opportunity for Prenatal Cellular Therapy

Rachel Sagar¹, Lilian Walther-Jallow², Anna L David^{1

3}, Cecilia Götherström², Magnus Westgren²

Affiliations

¹ 1Institute for Women's Health, University College London, 86-96 Chenies Mews, London, WC1E 6HX UK.
² 2Department of Clinical Science, Intervention and Technology, K57, Division of Obstetrics and Gynecology, Karolinska University Hospital Huddinge, Karolinska Institutet, 141 86 Stockholm, Sweden.
³ 3Katholieke Universiteit Leuven, Oude Markt 13, 3000 Leuven, Belgium.

PMID: 29600162
PMCID: PMC5866262
DOI: 10.1007/s40778-018-0118-8

Review

Fetal Mesenchymal Stromal Cells: an Opportunity for Prenatal Cellular Therapy

Rachel Sagar et al. Curr Stem Cell Rep. 2018.

. 2018;4(1):61-68.

doi: 10.1007/s40778-018-0118-8. Epub 2018 Feb 15.

Authors

Rachel Sagar¹, Lilian Walther-Jallow², Anna L David^{1

3}, Cecilia Götherström², Magnus Westgren²

Affiliations

¹ 1Institute for Women's Health, University College London, 86-96 Chenies Mews, London, WC1E 6HX UK.
² 2Department of Clinical Science, Intervention and Technology, K57, Division of Obstetrics and Gynecology, Karolinska University Hospital Huddinge, Karolinska Institutet, 141 86 Stockholm, Sweden.
³ 3Katholieke Universiteit Leuven, Oude Markt 13, 3000 Leuven, Belgium.

PMID: 29600162
PMCID: PMC5866262
DOI: 10.1007/s40778-018-0118-8

Abstract

Purpose of review: The aim of the study is to provide an overview on the possibility of treating congenital disorders prenatally with mesenchymal stromal cells (MSCs).

Recent findings: MSCs have multilineage potential and a low immunogenic profile and are immunomodulatory and more easy to expand in culture. Their ability to migrate, engraft and differentiate, or act via a paracrine effect on target tissues makes MSCs candidates for clinical therapies. Fetal and extra-fetal MSCs offer higher therapeutic potential compared to MSCs derived from adult sources.

Summary: MSCs may be safely transplanted prenatally via ultrasound-guided injection into the umbilical cord. Due to these characteristics, fetal MSCs are of great interest in the field of in utero stem cell transplantation for treatment of congenital disease.

Keywords: In utero stem cell transplantation; Mesenchymal stromal cells; Prenatal therapy.

PubMed Disclaimer

Conflict of interest statement

Compliance with Ethical StandardsRachel Sagar, Lilian Walther-Jallow, Anna L. David, Cecilia Götherström, and Magnus Westgren are members of the BOOSTB4 consortium. Cecilia Götherström is the consortium leader for the study Boost Brittle Bones Before Birth (BOOSTB4). Magnus Westgren and Cecilia Götherström are shareholders in a company Cellprotect AB working on different stem cell therapies.This article does not contain any studies with human or animal subjects performed by any of the authors.

Cited by

Current Overview of Osteogenesis Imperfecta.
Deguchi M, Tsuji S, Katsura D, Kasahara K, Kimura F, Murakami T. Deguchi M, et al. Medicina (Kaunas). 2021 May 10;57(5):464. doi: 10.3390/medicina57050464. Medicina (Kaunas). 2021. PMID: 34068551 Free PMC article. Review.
Stakeholder views and attitudes towards prenatal and postnatal transplantation of fetal mesenchymal stem cells to treat Osteogenesis Imperfecta.
Hill M, Lewis C, Riddington M, Crowe B, DeVile C, David AL, Semler O, Westgren M, Götherström C, Chitty LS. Hill M, et al. Eur J Hum Genet. 2019 Aug;27(8):1244-1253. doi: 10.1038/s41431-019-0387-4. Epub 2019 Mar 27. Eur J Hum Genet. 2019. PMID: 30918362 Free PMC article. Clinical Trial.
In utero Exposure to Maternal Chronic Inflammation Transfers a Pro-Inflammatory Profile to Generation F2 via Sex-Specific Mechanisms.
Adams RCM, Smith C. Adams RCM, et al. Front Immunol. 2020 Feb 13;11:48. doi: 10.3389/fimmu.2020.00048. eCollection 2020. Front Immunol. 2020. PMID: 32117231 Free PMC article.
Fetal adnexa-derived allogeneic mesenchymal stem cells for cardiac regeneration: the future trend of cell-based therapy for age-related adverse conditions.
Gorjipour F, Bohloolighashghaei S, Sotoudeheian M, Pazoki Toroudi H. Gorjipour F, et al. Hum Cell. 2025 Feb 25;38(2):61. doi: 10.1007/s13577-025-01190-2. Hum Cell. 2025. PMID: 39998714 Review.
Immunomodulatory effect of IFN-γ licensed adipose-mesenchymal stromal cells in an in vitro model of inflammation generated by SARS-CoV-2 antigens.
Bispo ECI, Argañaraz ER, Neves FAR, de Carvalho JL, Saldanha-Araujo F. Bispo ECI, et al. Sci Rep. 2024 Oct 16;14(1):24235. doi: 10.1038/s41598-024-75776-5. Sci Rep. 2024. PMID: 39415027 Free PMC article.

See all "Cited by" articles

References

1. Friedenstein AJ, Piatetzky-Shapiro II, Petrakova KV. Osteogenesis in transplants of bone marrow cells. Development. 1966;16:381–390. - PubMed
1. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317. doi: 10.1080/14653240600855905. - DOI - PubMed
1. Trounson A, Thakar RG, Lomax G, Gibbons D. Clinical trials for stem cell therapies. BMC Med. 2011;9(2011):52. doi: 10.1186/1741-7015-9-52. - DOI - PMC - PubMed
1. Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell. 2015;17(1):11–22. doi: 10.1016/j.stem.2015.06.007. - DOI - PubMed
1. Osiris receives second approval for life-saving stem cell drug; prochymal granted marketing consent by New Zealand http://investor.osiris.com/releasedetail.cfm?Releaseid=683073 Accessed 1/11/2017.

Publication types

Actions

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Other Literature Sources
- scite Smart Citations
Research Materials
- NCI CPTC Antibody Characterization Program

[1] Friedenstein AJ, Piatetzky-Shapiro II, Petrakova KV. Osteogenesis in transplants of bone marrow cells. Development. 1966;16:381–390. - PubMed

[2] Friedenstein AJ, Piatetzky-Shapiro II, Petrakova KV. Osteogenesis in transplants of bone marrow cells. Development. 1966;16:381–390. - PubMed

[3] Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317. doi: 10.1080/14653240600855905. - DOI - PubMed

[4] Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317. doi: 10.1080/14653240600855905. - DOI - PubMed

[5] Trounson A, Thakar RG, Lomax G, Gibbons D. Clinical trials for stem cell therapies. BMC Med. 2011;9(2011):52. doi: 10.1186/1741-7015-9-52. - DOI - PMC - PubMed

[6] Trounson A, Thakar RG, Lomax G, Gibbons D. Clinical trials for stem cell therapies. BMC Med. 2011;9(2011):52. doi: 10.1186/1741-7015-9-52. - DOI - PMC - PubMed

[7] Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell. 2015;17(1):11–22. doi: 10.1016/j.stem.2015.06.007. - DOI - PubMed

[8] Trounson A, McDonald C. Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell. 2015;17(1):11–22. doi: 10.1016/j.stem.2015.06.007. - DOI - PubMed

[9] Osiris receives second approval for life-saving stem cell drug; prochymal granted marketing consent by New Zealand http://investor.osiris.com/releasedetail.cfm?Releaseid=683073 Accessed 1/11/2017.

[10] Osiris receives second approval for life-saving stem cell drug; prochymal granted marketing consent by New Zealand http://investor.osiris.com/releasedetail.cfm?Releaseid=683073 Accessed 1/11/2017.

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Fetal Mesenchymal Stromal Cells: an Opportunity for Prenatal Cellular Therapy

Affiliations

Fetal Mesenchymal Stromal Cells: an Opportunity for Prenatal Cellular Therapy

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources

Research Materials